Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today participated in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. Read the transcript from this chat that features Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity.
Transcript: Oppenheimer 32nd Annual Healthcare Conference